Normalization of the microbiota in patients after treatment for colonic lesions
© The Author(s) 2017
Received: 19 September 2017
Accepted: 31 October 2017
Published: 16 November 2017
Colorectal cancer is a worldwide health problem. Despite growing evidence that members of the gut microbiota can drive tumorigenesis, little is known about what happens to it after treatment for an adenoma or carcinoma. This study tested the hypothesis that treatment for adenoma or carcinoma alters the abundance of bacterial populations associated with disease to those associated with a normal colon. We tested this hypothesis by sequencing the 16S rRNA genes in the feces of 67 individuals before and after treatment for adenoma (N = 22), advanced adenoma (N = 19), and carcinoma (N = 26).
There were small changes to the bacterial community associated with adenoma or advanced adenoma and large changes associated with carcinoma. The communities from patients with carcinomas changed significantly more than those with adenoma following treatment (P value < 0.001). Although treatment was associated with intrapersonal changes, the change in the abundance of individual OTUs in response to treatment was not consistent within diagnosis groups (P value > 0.05). Because the distribution of OTUs across patients and diagnosis groups was irregular, we used the random forest machine learning algorithm to identify groups of OTUs that could be used to classify pre and post-treatment samples for each of the diagnosis groups. Although the adenoma and carcinoma models could reliably differentiate between the pre- and post-treatment samples (P value < 0.001), the advanced-adenoma model could not (P value = 0.61). Furthermore, there was little overlap between the OTUs that were indicative of each treatment. To determine whether individuals who underwent treatment were more likely to have OTUs associated with normal colons we used a larger cohort that contained individuals with normal colons and those with adenomas, advanced adenomas, and carcinomas. We again built random forest models and measured the change in the positive probability of having one of the three diagnoses to assess whether the post-treatment samples received the same classification as the pre-treatment samples. Samples from patients who had carcinomas changed toward a microbial milieu that resembles the normal colon after treatment (P value < 0.001). Finally, we were unable to detect any significant differences in the microbiota of individuals treated with surgery alone and those treated with chemotherapy or chemotherapy and radiation (P value > 0.05).
By better understanding the response of the microbiota to treatment for adenomas and carcinomas, it is likely that biomarkers will eventually be validated that can be used to quantify the risk of recurrence and the likelihood of survival. Although it was difficult to identify significant differences between pre- and post-treatment samples from patients with adenoma and advanced adenoma, this was not the case for carcinomas. Not only were there large changes in pre- versus post-treatment samples for those with carcinoma, but also these changes were toward a more normal microbiota.
Colorectal cancer (CRC) is the third most common cause of cancer deaths in the USA [1, 2]. Disease mortality has significantly decreased, predominately due to improvements in screening . Despite these improvements, there are still approximately 50,000 CRC-related deaths per year in the USA . Current estimates indicate that 20–30% of those who undergo treatment will experience recurrence and 35% of all patients will die within 5 years [3–5]. Identification of methods to assess patients’ risk of recurrence is of great importance to reduce mortality and healthcare costs.
There is growing evidence that the gut microbiota is involved in the progression of CRC. Mouse-based studies have identified populations of Bacteroides fragilis, Escherichia coli, and Fusobacterium nucleatum that alter disease progression [6–10]. Furthermore, studies that shift the structure of the microbiota through the use of antibiotics or inoculation of germ-free mice with human feces have shown that varying community compositions can result in varied tumor burden [11–13]. Collectively, these studies support the hypothesis that the microbiota can alter the amount of inflammation in the colon and with it the rate of tumorigenesis .
Building upon this evidence, several human studies have identified unique signatures of colonic lesions [15–20]. One line of research has identified community-level differences between those bacteria that are found on and adjacent to colonic lesions and have supported a role for B. fragilis, E. coli, and F. nucleatum in tumorigenesis [21–23]. Others have proposed feces-based biomarkers that could be used to diagnose the presence of colonic adenomas and carcinomas [24–26]. These studies have associated F. nucleatum and other oral pathogens with colonic lesions (adenoma, advanced adenoma, and carcinoma). They have also noted that the loss of bacteria generally thought to produce short-chain fatty acids, which can suppress inflammation, is associated with colonic lesions. This suggests that gut bacteria have a role in tumorigenesis with potential as useful biomarkers for aiding in the early detection of disease [21–26].
Despite advances in understanding the role between the gut microbiota and colonic tumorigenesis, we still do not understand how treatments including resection, chemotherapy, and/or radiation affect the composition of the gut microbiota. If the microbial community drives tumorigenesis then one would hypothesize that treatment to remove a lesion would not only remove the lesion, but also the microbiota that promoted the tumorigenesis and hence the risk of recurrence. To test this hypothesis, we addressed two related questions: does treatment affect the colonic microbiota in a predictable manner? If so, does the treatment alter the community to more closely resemble that of individuals with normal colons?
We answered these questions by sequencing the V4 region of 16S rRNA genes amplified from fecal samples of individuals with adenoma, advanced adenoma, and carcinomas pre- and post-treatment. We used classical community analysis to compare the alpha and beta-diversity of communities pre- and post-treatment. Next, we generated random forest models to identify bacterial populations that were indicative of treatment for each diagnosis group. Finally, we measured the predictive probabilities to assess whether treatment yielded bacterial communities similar to those individuals with normal colons. We found that treatment alters the composition of the gut microbiota and that, for those with carcinomas, the gut microbiota shifted more toward that of a normal colon after treatment. In the individuals with carcinomas, no difference was found by the type of treatment (surgery alone, surgery with chemotherapy, surgery with chemotherapy, and radiation). Understanding how the community responds to these treatments could be a valuable tool for identifying biomarkers to quantify the risk of recurrence and the likelihood of survival.
Treatment for colonic lesions alters the bacterial community structure
Demographic data of patients in the pre and post-treatment cohort
Age (mean ± SD)
61.68 ± 7.2
63.11 ± 10.9
61.65 ± 12.9
BMI (mean ± SD)
26.86 ± 3.9
25.81 ± 4.7
28.63 ± 7.2
Days between colonoscopy (mean ± SD)
255.41 ± 42
250.16 ± 41
350.85 ± 102
Surgery and chemotherapy
Surgery, chemotherapy, and radiation
Demographic data of training cohort
Age (mean ± SD)
54.29 ± 9.9
63.01 ± 13.1
64.07 ± 11.3
64.37 ± 12.9
BMI (mean ± SD)
26.97 ± 5.3
25.69 ± 4.8
26.66 ± 4.9
29.27 ± 6.7
Difficult to identify effects of specific treatments on the change in the microbiota. The type of treatment that the patients received varied across diagnosis groups. Those with adenomas and advanced adenomas received surgical resection (adenoma, N=4; advanced adenoma, N=4) or polyp removal during colonoscopy (adenoma, N=18; advanced adenoma, N=15) and those with carcinomas received surgical resection (N=12), surgical resection with chemotherapy (N=9), and surgical resection with chemotherapy and radiation (N=5). Regardless of treatment used, there was no significant difference in the effect of these treatments on the number of observed OTUs, Shannon diversity, or Shannon evenness (P value > 0.05). Furthermore, there was not a significant difference in the effect of the treatments on the amount of change in the community structure (P value = 0.375). Finally, the change in the positive probability was not significantly different between any of the treatment groups (P value = 0.375). Due to the relatively small number of samples in each treatment group, it was difficult to make a definitive statement regarding the specific type of treatment on the amount of change in the structure of the microbiota.
Our study focused on comparing the microbiota of patients diagnosed with adenoma, advanced adenoma, and carcinoma before and after treatment. For all three groups of patients, we observed changes in their microbiota. Some of these changes, specifically for adenoma, may be due to normal temporal variation, however, those with advanced adenoma and carcinoma clearly had large microbiota changes. After treatment, the microbiota of patients with carcinoma changed significantly more than the other groups. This change resulted in communities that more closely resembled those of patients with a normal colon. This may suggest that treatment for carcinoma is not only successful for removing the carcinoma but also at reducing the associated bacterial communities. Understanding the effect of treatment on the microbiota of those diagnosed with carcinomas may have important implications for reducing disease recurrence. It is intriguing that it may be possible to use microbiome-based biomarkers to not only predict the presence of lesions but to also assess the risk of recurrence due to these changes in the microbiota.
Patients diagnosed with adenoma and advanced adenoma, however, did not experience a shift toward a community structure that resembled those with normal colons. This may be due to the fundamental differences between the features of adenomas and advanced adenomas and carcinoma. Specifically, carcinomas may create an inflammatory milieu that would impact the structure of the community and removal of that stimulus would alter said structure. It is possible that the difference between the microbiota of patients with adenoma and advanced adenoma and those with normal colons is subtle. This is supported by the reduced ability of our models to correctly classify patients with adenomas and advanced adenomas relative to those diagnosed with carcinomas [Additional file 2: Figure S1]. Given the irregular distribution of microbiota across patients in the different diagnosis groups, it is possible that we lacked the statistical power to adequately characterize the change in the communities following treatment.
There was a subset of patients (7 of the 26 with carcinomas) who demonstrated an elevated probability of carcinoma after treatment. This may reflect an elevated risk of recurrence. The 26.92% prevalence of increased carcinoma probability from our study is within the expected rate of recurrence (20–30% (3, 4)). We hypothesized that these individuals may have had more severe tumors; however, the tumor severity of these seven individuals (1 with stage I, 3 with stage II, and 3 with stage III) was similar to the distribution observed among the other 19 patients. We also hypothesized that we may have sampled these patients later than the rest, and their communities may have reverted to a carcinoma-associated state; however, there was not a statistically significant difference in the length of time between sample collection among those whose probabilities increased (331 (246–358) days) or decreased (364 (301–434) days) (Wilcoxon test; P value = 0.39) (all days data displayed as median (IQR)). Finally, it is possible that these patients may not have responded to treatment as well as the other 19 patients diagnosed with carcinoma and so the microbiota may not have been impacted the same way. Again, further studies looking at the role of the microbiota in recurrence are needed to understand the dynamics following treatment.
Our final hypothesis was that the specific type of treatment altered the structure of the microbiome. The treatment to remove adenomas and advanced adenomas was either polyp removal or surgical resection whereas it was surgical resection alone or in combination with chemotherapy or with chemotherapy and radiation for individuals with carcinoma. Because chemotherapy and radiation target rapidly growing cells, these treatments would be more likely to cause a turnover of the colonic epithelium driving a more significant change in the structure of the microbiota. Although, we were able to test for an effect across these specific types of treatment, the number of patients in each treatment group was relatively small. Finally, those undergoing surgery would have received antibiotics, and this may be a potential confounder. However, our pre-treatment stool samples were obtained before the surgery and the post-treatment samples were obtained long after any effects due to antibiotic administration on the microbiome would be expected to occur (344 (266–408) days). We also found no difference in the community structure of those that received surgery and those that did not as a treatment for adenoma or advanced adenoma.
This study expands upon existing research that has established a role for the microbiota in tumorigenesis and that demonstrated the utility of microbiome-based biomarkers to predict the presence of colonic lesions. We were surprised by the lack of a consistent signal that was associated with treatment of patients with adenomas or advanced adenomas. The lack of a large effect size may be due to differences in the role of bacteria in the formation of adenomas and carcinomas or it could be due to differences in the behaviors and medications within these classes of patients. One of the most exciting of these future directions is the possibility that markers within the microbiota could be used to potentially evaluate the effect of treatment and to predict recurrence for those diagnosed with carcinoma. If such an approach is effective, it might be possible to target the microbiota as part of adjuvant therapy, if the biomarkers identified play a key role in the disease process. Our data provides additional evidence on the importance of the microbiota in tumorigenesis by addressing the recovery of the microbiota after treatment and opens interesting avenues of research into how these changes may affect recurrence.
Study design and patient sampling
Sampling and design have been previously reported in Baxter et al. . Briefly, samples were stored on ice for at least 24 h before freezing. Although we cannot exclude that this sampling protocol may have impacted the gut microbiota composition, all samples were subjected to the same methodology. Study exclusion involved those who had already undergone surgery, radiation, or chemotherapy, had colorectal cancer before a baseline fecal sample could be obtained, had IBD, a known hereditary non-polyposis colorectal cancer, or familial adenomatous polyposis. Samples used to build the models for prediction were collected either prior to a colonoscopy or between 1 and 2 weeks after initial colonoscopy. The bacterial community has been shown to normalize back to a pre-colonoscopy community within this time period . Our study cohort consisted of 67 individuals with an initial sample as described and a follow-up sample obtained between 188 and 546 days after treatment of lesion [Table 1]. Patients were diagnosed by colonoscopic examination and histopathological review of any biopsies taken. Patients were classified as having advanced adenoma if they had an adenoma greater than 1 cm, more than three adenomas of any size, or an adenoma with villous histology. This study was approved by the University of Michigan Institutional Review Board. All study participants provided informed consent, and the study itself conformed to the guidelines set out by the Helsinki Declaration. The original protocol for the study did not provide for tracking patients after the follow-up samples and so it was not possible for us to ascertain their diagnosis after the completion of the study.
For this study, treatment refers specifically to the removal of a lesion with or without chemotherapy and radiation. The majority of patients undergoing treatment for adenoma or advanced adenoma were not treated surgically [Table 1] but rather via colonoscopy. All patients diagnosed with carcinomas were treated with at least surgery or a combination of surgery and chemotherapy or surgery, chemotherapy, and radiation. The type of chemotherapy used for patients with CRC included Oxaliplatin, Levicovorin, Folfox, Xeloda, Capecitabine, Avastin, Fluorouracil, and Glucovorin. These were used individually or in combination with others depending on the patient [Table 1]. If an individual was treated with radiation, they were also always treated with chemotherapy. Radiation therapy generally used 18 mV photons for treatment.
16S rRNA gene sequencing
Sequencing was completed as described by Kozich et al. . DNA extraction used the 96-well Soil DNA isolation kit (MO BIO Laboratories) and an epMotion 5075 automated pipetting system (Eppendorf). The V4 variable region was amplified, and the resulting product was split between four sequencing runs with normal, adenoma, and carcinoma evenly represented on each run. Each group was randomly assigned to avoid biases based on sample collection location. The pre and post-treatment samples were sequenced on the same run.
The mothur software package (v1.37.5) was used to process the 16S rRNA gene sequences and has been previously described . The general workflow using mothur included merging paired-end reads into contigs, filtering for low quality contigs, aligning to the SILVA database , screening for chimeras using UCHIME , classifying with a naive Bayesian classifier using the Ribosomal Database Project (RDP) , and clustered into operational taxonomic units (OTUs) using a 97% similarity cutoff with an average neighbor clustering algorithm . The number of sequences for each sample was rarefied to 10523 to minimize the impacts of uneven sampling.
The random forest  algorithm was used to create the three models used to classify pre- and post-treatment samples by diagnosis (adenoma, advanced adenoma, or carcinoma) as well as to assess the probability that a sample was more similar to the patient’s original diagnosis or that of a disease-free patient. All models included only OTU data obtained from 16S rRNA sequencing and were processed using the caret (v6.0.76) R package. For each model, we optimized the mtry hyper-parameter, which defines the number of OTUs to investigate at each split before a new division of the data was created with the random forest model . To insure that our optimization did not result in over-fitting of the data, we made 100 different 80/20 (train/test) splits of the data where the same proportion was present within both the whole data set and the 80/20 split. For each of the 100 splits, 20 repeated 10-fold cross validation was performed on the 80% component to optimize the mtry hyper-parameter by maximizing the AUC (area under the curve of the receiver operator characteristic). The resulting model was then tested on the 20% of the data that were held out. A summary of the mtry hyperparameter values that were tried is available in Additional file 1: Table S5. The reported P values for each model relative to a random labeling was assessed by comparing the distribution of the 100 80/20 splits for the correctly labeled data to the distribution of randomly labeled data.
The three diagnosis models were constructed by using the data from Baxter et al. , which was censored for the pre-treatment samples of the patients that we had post-treatment samples. The treatment models were then used to quantify the model probability that a patient with an initial diagnosis retained that diagnosis or a disease-free diagnosis.
The R software package (v3.4.1) was used for all statistical analysis. Comparisons between bacterial community structure utilized PERMANOVA  in the vegan package (v2.4.3). Comparisons between probabilities as well as overall differences in the median relative abundance of each OTU between pre- and post-treatment samples utilized a paired Wilcoxon ranked sum test. Comparisons between different treatment for lesions utilized a Kruskal-Wallis test. Where multiple comparison testing was appropriate, a Benjamini-Hochberg (BH) correction was applied  and a corrected P value of less than 0.05 was considered significant. The P values reported are those that were BH corrected. Model rank importance was determined by obtaining the median MDA from the 100, 20 repeated 10-fold cross validation and then ranking from largest to smallest MDA.
A detailed and reproducible description of how the data were processed and analyzed can be found at https://github.com/SchlossLab/Sze_FollowUps_Microbiome_2017. Raw sequences have been deposited into the NCBI Sequence Read Archive (SRP062005 and SRP096978) and the necessary metadata can be found at https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/Traces/study/ and searching the respective SRA study accession.
The authors thank the Great Lakes-New England Early Detection Research Network for providing the fecal samples that were used in this study. We would also like to thank Amanda Elmore for reviewing and correcting code error and providing feedback on manuscript drafts. We would also like to thank Nicholas Lesniak for providing feedback on manuscript drafts.
This study was supported by funding from the National Institutes of Health to P. Schloss (R01GM099514, P30DK034933) and to the Early Detection Research Network (U01CA86400).
All authors were involved in the conception and design of the study. MAS analyzed the data. NTB processed the samples and analyzed the data. All authors interpreted the data. MAS and PDS wrote the manuscript. All authors reviewed and revised the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The University of Michigan Institutional Review Board approved this study, and all subjects provided informed consent. This study conformed to the guidelines of the Helsinki Declaration.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: Cancer J Clin. 2016; 66:7–30.Google Scholar
- Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009; 22:191–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Hellinger MD, Santiago CA. Reoperation for recurrent colorectal cancer. Clin Colon Rectal Surg. 2006; 19:228–36.View ArticlePubMedPubMed CentralGoogle Scholar
- Ryuk JP, Choi G-S, Park JS, Kim HJ, Park SY, Yoon GS, Jun SH, Kwon YC. Predictive factors and the prognosis of recurrence of colorectal cancer within 2 years after curative resection. Ann Surg Treat Res. 2014; 86:143–51.View ArticlePubMedPubMed CentralGoogle Scholar
- Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, (eds).SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/csr/1975_2014/.
- Goodwin AC, Destefano Shields CE, Wu S, Huso DL, Wu X, Murray-Stewart TR, Hacker-Prietz A, Rabizadeh S, Woster PM, Sears CL, Casero RA. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc Natl Acad Sci USA. 2011; 108:15354–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Abed J, Emgård JEM, Zamir G, Faroja M, Almogy G, Grenov A, Sol A, Naor R, Pikarsky E, Atlan KA, Mellul A, Chaushu S, Manson AL, Earl AM, Ou N, Brennan CA, Garrett WS, Bachrach G. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe. 2016; 20:215–25.View ArticlePubMedPubMed CentralGoogle Scholar
- Arthur JC, Gharaibeh RZ, Mühlbauer M, Perez-Chanona E, Uronis JM, McCafferty J, Fodor AA, Jobin C. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nature Commun. 2014; 5:4724.View ArticleGoogle Scholar
- Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold GL, El-Omar EM, Brenner D, Fuchs CS, Meyerson M, Garrett WS. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013; 14:207–15.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu S, Rhee K-J, Albesiano E, Rabizadeh S, Wu X, Yen H-R, Huso DL, Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM, Sears CL. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nature Med. 2009; 15:1016–22.View ArticlePubMedPubMed CentralGoogle Scholar
- Zackular JP, Baxter NT, Chen GY, Schloss PD. Manipulation of the gut microbiota reveals role in colon tumorigenesis. mSphere. 2016; 1:1–12.View ArticleGoogle Scholar
- Zackular JP, Baxter NT, Iverson KD, Sadler WD, Petrosino JF, Chen GY, Schloss PD. The gut microbiome modulates colon tumorigenesis. mBio. 2013; 4:e00692—00613.View ArticleGoogle Scholar
- Baxter NT, Zackular JP, Chen GY, Schloss PD. Structure of the gut microbiome following colonization with human feces determines colonic tumor burden. Microbiome. 2014; 2:20.View ArticlePubMedPubMed CentralGoogle Scholar
- Flynn KJ, Baxter NT, Schloss PD. Metabolic and community synergy of oral bacteria in colorectal cancer. mSphere. 2016; 1:1–6.View ArticleGoogle Scholar
- Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, Jia W, Cai S, Zhao L. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2012; 6:320–9.View ArticlePubMedGoogle Scholar
- Chen H-M, Yu Y-N, Wang J-L, Lin Y-W, Kong X, Yang C-Q, Yang L, Liu Z-J, Yuan Y-Z, Liu F, Wu J-X, Zhong L, Fang D-C, Zou W, Fang J-Y. Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. Am J Clin Nutr. 2013; 97:1044–52.View ArticlePubMedGoogle Scholar
- Chen W, Liu F, Ling Z, Tong X, Xiang C.Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PloS One. 2012; e39743:7.Google Scholar
- Shen XJ, Rawls JF, Randall T, Burcal L, Mpande CN, Jenkins N, Jovov B, Abdo Z, Sandler RS, Keku TO. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut Microbes. 2010; 1:138–47.View ArticlePubMedPubMed CentralGoogle Scholar
- Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, Garrett WS, Meyerson M. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012; 22:292–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, Zhang D, Xia H, Xu X, Jie Z, Su L, Li X, Li X, Li J, Xiao L, Huber-Schönauer U, Niederseer D, Xu X, Al-Aama JY, Yang H, Wang J, Kristiansen K, Arumugam M, Tilg H, Datz C, Wang J. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun. 2015; 6:6528.View ArticlePubMedGoogle Scholar
- Dejea CM, Wick EC, Hechenbleikner EM, White JR, Mark Welch JL, Rossetti BJ, Peterson SN, Snesrud EC, Borisy GG, Lazarev M, Stein E, Vadivelu J, Roslani AC, Malik AA, Wanyiri JW, Goh KL, Thevambiga I, Fu K, Wan F, Llosa N, Housseau F, Romans K, Wu X, McAllister FM, Wu S, Vogelstein B, Kinzler KW, Pardoll DM, Sears CL. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci USA. 2014; 111:18321–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA, Nosho K, Kostic AD, Giannakis M, Watanabe H, Bullman S, Milner DA, Harris CC, Giovannucci E, Garraway LA, Freeman GJ, Dranoff G, Chan AT, Garrett WS, Huttenhower C, Fuchs CS, Ogino S. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 2015; 1:653–61.View ArticlePubMedPubMed CentralGoogle Scholar
- Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan T-J, Campbell BJ, Abujamel T, Dogan B, Rogers AB, Rhodes JM, Stintzi A, Simpson KW, Hansen JJ, Keku TO, Fodor AA, Jobin C. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science (New York). 2012; 338:120–3.View ArticleGoogle Scholar
- Baxter NT, Ruffin MT, Rogers MAM, Schloss PD. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. Genome Med. 2016; 8:37.View ArticlePubMedPubMed CentralGoogle Scholar
- Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Böhm J, Brunetti F, Habermann N, Hercog R, Koch M, Luciani A, Mende DR, Schneider MA, Schrotz-King P, Tournigand C, Tran Van Nhieu J, Yamada T, Zimmermann J, Benes V, Kloor M, Ulrich CM, Knebel Doeberitz Mvon, Sobhani I, Bork P. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol. 2014; 10:766.View ArticlePubMedPubMed CentralGoogle Scholar
- Zackular JP, Rogers MAM, Ruffin MT, Schloss PD. The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res (Philadelphia). 2014; 7:1112–21.View ArticleGoogle Scholar
- O’Brien CL, Allison GE, Grimpen F, Pavli P. Impact of colonoscopy bowel preparation on intestinal microbiota. PloS ONE. 2013; e62815:8.Google Scholar
- Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol. 2013; 79:5112–20.View ArticlePubMedPubMed CentralGoogle Scholar
- Pruesse E, Quast C, Knittel K, Fuchs BM, Ludwig W, Peplies J, Glöckner FO, SILV A. A comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB. Nucleic Acids Res. 2007; 35:7188–96.View ArticlePubMedPubMed CentralGoogle Scholar
- Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics. (Oxford England). 2011; 27:2194–200.View ArticleGoogle Scholar
- Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007; 73:5261–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Schloss PD, Westcott SL. Assessing and improving methods used in operational taxonomic unit-based approaches for 16S rRNA gene sequence analysis. Appl Environ Microbiol. 2011; 77:3219–26.View ArticlePubMedPubMed CentralGoogle Scholar
- Breiman L. Random Forests. Mach Learn. 2001; 45:5–32.View ArticleGoogle Scholar
- Anderson MJ, Walsh DCI. PERMANOVA, ANOSIM, and the Mantel test in the face of heterogeneous dispersions: What null hypothesis are you testing?Ecol Monogr. 2013; 83:557–74.View ArticleGoogle Scholar
- Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B Methodol. 1995; 57:289–300.Google Scholar